Cooperation of BRAF F595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling

Activating BRAF mutations, in particular V600E/K, drive many cancers and are considered mutually exclusive with mutant RAS, whereas inactivating BRAF mutations in the D594F595G596 motif cooperate with RAS via paradoxical MEK/ERK activation. Due to the increasing use of comprehensive tumor genomic pr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kordes, Maximilian (VerfasserIn) , Heining, Christoph (VerfasserIn) , Hutter, Barbara (VerfasserIn) , Richter, Daniela (VerfasserIn) , Geörg, Christina (VerfasserIn) , Scholl, Claudia (VerfasserIn) , Gröschel, Stefan (VerfasserIn) , Roth, Wilfried (VerfasserIn) , Kalle, Christof von (VerfasserIn) , Jäger, Dirk (VerfasserIn) , Brors, Benedikt (VerfasserIn) , Weichert, Wilko (VerfasserIn) , Grüllich, Carsten (VerfasserIn) , Glimm, Hanno (VerfasserIn) , Fröhling, Stefan (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2016
In: Leukemia
Year: 2016, Jahrgang: 30, Heft: 4, Pages: 937-946
ISSN:1476-5551
DOI:10.1038/leu.2015.319
Online-Zugang:Verlag, Volltext: https://doi.org/10.1038/leu.2015.319
Verlag, Volltext: https://www.nature.com/articles/leu2015319
Volltext
Verfasserangaben:M. Kordes, M. Röring, C. Heining, S. Braun, B. Hutter, D. Richter, C. Geörg, C. Scholl, S. Gröschel, W. Roth, A. Rosenwald, E. Geissinger, C. von Kalle, D. Jäger, B. Brors, W. Weichert, C. Grüllich, H. Glimm, T. Brummer and S. Fröhling

MARC

LEADER 00000caa a2200000 c 4500
001 1683479696
003 DE-627
005 20220817164324.0
007 cr uuu---uuuuu
008 191126s2016 xx |||||o 00| ||eng c
024 7 |a 10.1038/leu.2015.319  |2 doi 
035 |a (DE-627)1683479696 
035 |a (DE-599)KXP1683479696 
035 |a (OCoLC)1341278802 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Kordes, Maximilian  |d 1985-  |e VerfasserIn  |0 (DE-588)120049119X  |0 (DE-627)1683623304  |4 aut 
245 1 0 |a Cooperation of BRAF F595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling  |c M. Kordes, M. Röring, C. Heining, S. Braun, B. Hutter, D. Richter, C. Geörg, C. Scholl, S. Gröschel, W. Roth, A. Rosenwald, E. Geissinger, C. von Kalle, D. Jäger, B. Brors, W. Weichert, C. Grüllich, H. Glimm, T. Brummer and S. Fröhling 
264 1 |c 2016 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Advance online publication, 18 December 2015 
500 |a Gesehen am 26.11.2019 
520 |a Activating BRAF mutations, in particular V600E/K, drive many cancers and are considered mutually exclusive with mutant RAS, whereas inactivating BRAF mutations in the D594F595G596 motif cooperate with RAS via paradoxical MEK/ERK activation. Due to the increasing use of comprehensive tumor genomic profiling, many non-V600 BRAF mutations are being detected whose functional consequences and therapeutic actionability are often unknown. We investigated an atypical BRAF mutation, F595L, which was identified along with mutant HRAS in histiocytic sarcoma and also occurs in epithelial cancers, melanoma and neuroblastoma, and determined its interaction with mutant RAS. Unlike other DFG motif mutants, BRAFF595L is a gain-of-function variant with intermediate activity that does not act paradoxically, but nevertheless cooperates with mutant RAS to promote oncogenic signaling, which is efficiently blocked by pan-RAF and MEK inhibitors. Mutation data from patients and cell lines show that BRAFF595L, as well as other intermediate-activity BRAF mutations, frequently coincide with mutant RAS in various cancers. These data define a distinct class of activating BRAF mutations, extend the spectrum of patients with systemic histiocytoses and other malignancies who are candidates for therapeutic blockade of the RAF-MEK-ERK pathway and underscore the value of comprehensive genomic testing for uncovering the vulnerabilities of individual tumors. 
700 1 |a Heining, Christoph  |e VerfasserIn  |0 (DE-588)1156392764  |0 (DE-627)1019233915  |0 (DE-576)502161981  |4 aut 
700 1 |a Hutter, Barbara  |e VerfasserIn  |0 (DE-588)14009752X  |0 (DE-627)61602293X  |0 (DE-576)314588760  |4 aut 
700 1 |a Richter, Daniela  |e VerfasserIn  |0 (DE-588)1034764632  |0 (DE-627)746269196  |0 (DE-576)382409329  |4 aut 
700 1 |a Geörg, Christina  |d 1981-  |e VerfasserIn  |0 (DE-588)1017957827  |0 (DE-627)690472315  |0 (DE-576)354690892  |4 aut 
700 1 |a Scholl, Claudia  |d 1971-  |e VerfasserIn  |0 (DE-588)128803533  |0 (DE-627)380643197  |0 (DE-576)187440271  |4 aut 
700 1 |a Gröschel, Stefan  |d 1979-  |e VerfasserIn  |0 (DE-588)138335664  |0 (DE-627)601621565  |0 (DE-576)307122352  |4 aut 
700 1 |a Roth, Wilfried  |d 1970-  |e VerfasserIn  |0 (DE-588)120891557  |0 (DE-627)080951279  |0 (DE-576)292433484  |4 aut 
700 1 |a Kalle, Christof von  |d 1962-  |e VerfasserIn  |0 (DE-588)1036481115  |0 (DE-627)75107926X  |0 (DE-576)168957396  |4 aut 
700 1 |a Jäger, Dirk  |d 1964-  |e VerfasserIn  |0 (DE-588)1032507535  |0 (DE-627)738505323  |0 (DE-576)380074125  |4 aut 
700 1 |a Brors, Benedikt  |e VerfasserIn  |0 (DE-588)1112102965  |0 (DE-627)866068732  |0 (DE-576)476376157  |4 aut 
700 1 |a Weichert, Wilko  |d 1970-2023  |e VerfasserIn  |0 (DE-588)123509106  |0 (DE-627)56134650X  |0 (DE-576)293740461  |4 aut 
700 1 |a Grüllich, Carsten  |d 1965-  |e VerfasserIn  |0 (DE-588)14101914X  |0 (DE-627)624500985  |0 (DE-576)321797981  |4 aut 
700 1 |a Glimm, Hanno  |d 1967-  |e VerfasserIn  |0 (DE-588)113880677  |0 (DE-627)51985120X  |0 (DE-576)289777879  |4 aut 
700 1 |a Fröhling, Stefan  |d 1969-  |e VerfasserIn  |0 (DE-588)120890046  |0 (DE-627)080950302  |0 (DE-576)188733930  |4 aut 
773 0 8 |i Enthalten in  |t Leukemia  |d London : Springer Nature, 1997  |g 30(2016), 4, Seite 937-946  |h Online-Ressource  |w (DE-627)32046699X  |w (DE-600)2008023-2  |w (DE-576)094139733  |x 1476-5551  |7 nnas  |a Cooperation of BRAF F595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling 
773 1 8 |g volume:30  |g year:2016  |g number:4  |g pages:937-946  |g extent:10  |a Cooperation of BRAF F595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling 
856 4 0 |u https://doi.org/10.1038/leu.2015.319  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u https://www.nature.com/articles/leu2015319  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20191126 
993 |a Article 
994 |a 2016 
998 |g 120890046  |a Fröhling, Stefan  |m 120890046:Fröhling, Stefan  |d 140000  |e 140000PF120890046  |k 0/140000/  |p 20  |y j 
998 |g 113880677  |a Glimm, Hanno  |m 113880677:Glimm, Hanno  |d 140000  |e 140000PG113880677  |k 0/140000/  |p 18 
998 |g 14101914X  |a Grüllich, Carsten  |m 14101914X:Grüllich, Carsten  |d 140000  |e 140000PG14101914X  |k 0/140000/  |p 17 
998 |g 123509106  |a Weichert, Wilko  |m 123509106:Weichert, Wilko  |d 910000  |d 912000  |e 910000PW123509106  |e 912000PW123509106  |k 0/910000/  |k 1/910000/912000/  |p 16 
998 |g 1112102965  |a Brors, Benedikt  |m 1112102965:Brors, Benedikt  |d 140000  |e 140000PB1112102965  |k 0/140000/  |p 15 
998 |g 1032507535  |a Jäger, Dirk  |m 1032507535:Jäger, Dirk  |d 140000  |e 140000PJ1032507535  |k 0/140000/  |p 14 
998 |g 1036481115  |a Kalle, Christof von  |m 1036481115:Kalle, Christof von  |d 140000  |e 140000PK1036481115  |k 0/140000/  |p 13 
998 |g 120891557  |a Roth, Wilfried  |m 120891557:Roth, Wilfried  |p 10 
998 |g 138335664  |a Gröschel, Stefan  |m 138335664:Gröschel, Stefan  |d 140000  |e 140000PG138335664  |k 0/140000/  |p 9 
998 |g 128803533  |a Scholl, Claudia  |m 128803533:Scholl, Claudia  |d 140000  |e 140000PS128803533  |k 0/140000/  |p 8 
998 |g 1017957827  |a Geörg, Christina  |m 1017957827:Geörg, Christina  |d 140000  |e 140000PG1017957827  |k 0/140000/  |p 7 
998 |g 1034764632  |a Richter, Daniela  |m 1034764632:Richter, Daniela  |d 140000  |e 140000PR1034764632  |k 0/140000/  |p 6 
998 |g 14009752X  |a Hutter, Barbara  |m 14009752X:Hutter, Barbara  |d 140000  |e 140000PH14009752X  |k 0/140000/  |p 5 
998 |g 1156392764  |a Heining, Christoph  |m 1156392764:Heining, Christoph  |d 140000  |e 140000PH1156392764  |k 0/140000/  |p 3 
998 |g 120049119X  |a Kordes, Maximilian  |m 120049119X:Kordes, Maximilian  |d 50000  |e 50000PK120049119X  |k 0/50000/  |p 1  |x j 
999 |a KXP-PPN1683479696  |e 3550019386 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"role":"aut","given":"Maximilian","family":"Kordes","display":"Kordes, Maximilian"},{"display":"Heining, Christoph","role":"aut","given":"Christoph","family":"Heining"},{"given":"Barbara","role":"aut","family":"Hutter","display":"Hutter, Barbara"},{"given":"Daniela","role":"aut","family":"Richter","display":"Richter, Daniela"},{"display":"Geörg, Christina","family":"Geörg","given":"Christina","role":"aut"},{"given":"Claudia","role":"aut","family":"Scholl","display":"Scholl, Claudia"},{"display":"Gröschel, Stefan","family":"Gröschel","given":"Stefan","role":"aut"},{"display":"Roth, Wilfried","family":"Roth","role":"aut","given":"Wilfried"},{"display":"Kalle, Christof von","role":"aut","given":"Christof von","family":"Kalle"},{"family":"Jäger","role":"aut","given":"Dirk","display":"Jäger, Dirk"},{"family":"Brors","given":"Benedikt","role":"aut","display":"Brors, Benedikt"},{"display":"Weichert, Wilko","family":"Weichert","role":"aut","given":"Wilko"},{"family":"Grüllich","given":"Carsten","role":"aut","display":"Grüllich, Carsten"},{"display":"Glimm, Hanno","role":"aut","given":"Hanno","family":"Glimm"},{"display":"Fröhling, Stefan","family":"Fröhling","role":"aut","given":"Stefan"}],"relHost":[{"disp":"Cooperation of BRAF F595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signalingLeukemia","recId":"32046699X","physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["1476-5551"],"eki":["32046699X"],"zdb":["2008023-2"]},"title":[{"subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal","title_sort":"Leukemia","title":"Leukemia"}],"part":{"text":"30(2016), 4, Seite 937-946","extent":"10","issue":"4","pages":"937-946","volume":"30","year":"2016"},"type":{"media":"Online-Ressource","bibl":"periodical"},"language":["eng"],"note":["Gesehen am 15.03.04"],"origin":[{"publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group","dateIssuedKey":"1997","dateIssuedDisp":"1997-","publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke"}],"pubHistory":["Nachgewiesen 11.1997 -"]}],"origin":[{"dateIssuedDisp":"2016","dateIssuedKey":"2016"}],"note":["Advance online publication, 18 December 2015","Gesehen am 26.11.2019"],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title_sort":"Cooperation of BRAF F595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling","title":"Cooperation of BRAF F595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling"}],"physDesc":[{"extent":"10 S."}],"recId":"1683479696","name":{"displayForm":["M. Kordes, M. Röring, C. Heining, S. Braun, B. Hutter, D. Richter, C. Geörg, C. Scholl, S. Gröschel, W. Roth, A. Rosenwald, E. Geissinger, C. von Kalle, D. Jäger, B. Brors, W. Weichert, C. Grüllich, H. Glimm, T. Brummer and S. Fröhling"]},"id":{"doi":["10.1038/leu.2015.319"],"eki":["1683479696"]}} 
SRT |a KORDESMAXICOOPERATIO2016